传IBM研究出售人工智能医疗护理数据分支IBM Watson Health
《华尔街日报》引述消息报道,国际商业机器(IBM)(IBM.US)正研究出售旗下人工智能医疗护理分支IBM Watson Health。
该分支为医院、保险公司及药厂提供数据管理服务,年收入约10亿美元,目前仍未盈利。分支旗下品牌包括分析乳房X光检查及磁力共振图片的Merge Healthcare,协助与病人沟通的Phytel及分析医疗数据的Truven Health Analysis。
报道指公司正考虑多个方案,包括向私募基金及业界出售,或透过与一间特殊目的收购公司(SPAC)合并实现上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.